
    
      This trial is multicentre, randomised, double-blinded, Phase II, parallel group comparison
      study of the efficacy and safety of FP-1201-lyo compared to placebo in patients surviving
      emergency open surgery for an infra-renal ruptured abdominal aortic aneurysm. Investigational
      medicinal product will be administered as post-surgical preventive treatment either 10Âµg
      FP-1201-lyo or placebo. Treatment will be administered daily every 24 hrs for 6 days. The
      first dose will be given after successful surgery at the point when the patient arrives to
      the Intensive Care Unit (ICU).

      Both treatment groups will receive standard supportive care.

      Aim is randomise and initiate treatment of 152 patients. For the final analysis, a minimum of
      129 evaluable patients will be required.
    
  